BrainCool 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Jon Berg

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	4.8yrs
CEO 소유권	n/a
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	less than a year

최근 관리 업데이트

Recent updates

How Much Did BrainCool's(NGM:BRAIN) Shareholders Earn From Share Price Movements Over The Last Five Years?

Jan 14

CEO

Jon Berg

4.8yrs

테뉴어

Mr. Jon Berg serves as Chief Operating Officer at BrainCool AB (publ) from 2020 and serves as its Chief Executive Officer from February 2024 and served as its Development & Quality Assurance Manager. Mr. B...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jon Berg	CEO & COO	4.8yrs	데이터 없음	데이터 없음
Lotta Valfridsson	Chief Financial Officer	1.8yrs	데이터 없음	0.049% SEK 207.6k
Jimmy Hedenstjerna	Chief Technology Officer	less than a year	데이터 없음	데이터 없음
Christian Strand	Head of Distribution & Sales	less than a year	데이터 없음	데이터 없음
Oscar Engellau	Executive Director	no data	데이터 없음	데이터 없음
Mohammad Fazel	Head of Clinical Studies	6.8yrs	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

경험이 풍부한 관리: BRAIN 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Oscar Engellau	Executive Director	1.8yrs	데이터 없음	데이터 없음
Hans Henriksson	Chairman of the Board	10.8yrs	데이터 없음	데이터 없음
Jens Lindberg	Independent Director	less than a year	데이터 없음	데이터 없음
Klaus Bratlie	Independent Director	less than a year	데이터 없음	데이터 없음
Michelle Hessius	Independent Director	less than a year	데이터 없음	데이터 없음

0.4yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: BRAIN 의 이사회는 경험(평균 재직 기간 0.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

BrainCool 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Braincool AB (Publ) Approves Board Appointments

BrainCool AB (publ) Announces Roger Henriksson Declines Re-Election as Board Member

CEO & Director recently sold kr254k worth of stock

CEO & Director recently bought kr53k worth of stock

CEO & Director recently bought kr62k worth of stock

No independent directors

Recent updates

Third quarter 2024 earnings released

Second quarter 2024 earnings released

Braincool AB (Publ) Approves Board Appointments

BrainCool AB (publ) Announces Roger Henriksson Declines Re-Election as Board Member

BrainCool AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 85.763172 million.

BrainCool AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 85.763172 million.

BrainCool AB (publ) to Report Fiscal Year 2024 Results on Feb 10, 2025

Full year 2023 earnings released

Braincool AB (Publ) Announces Karolinska Starts the Clinical Study PRINCESS 2 with BrainCool's Product RhinoChill® System

New major risk - Share price stability

BrainCool AB (publ) and University of Freiburg Announces Start of Pivotal Clinical Trial (Cottis 2) for Combined Target Temperature Management and Thrombectomy After Ischemic Stroke

CEO & Director recently sold kr254k worth of stock

Third quarter 2023 earnings released

Braincool AB (Publ) Announces New Clinical Study Evaluating Early Hypothermia Treatment After Cardiac Arrest with the Braincool System and Rhinochill System

CEO & Director recently bought kr53k worth of stock

American Medical Association Approves New Current Procedural Terminology Code for Cryotherapy Using BrainCool's Cooral System

BrainCool AB (publ) Announces New CPT Code from AMA for Cooral® System supports Pathway to Reimbursement in the U.S

CEO & Director recently bought kr62k worth of stock

Second quarter 2023 earnings released

New major risk - Share price stability

Braincool AB (Publ) Introduces Minichill in Japan

Braincool AB (Publ) Announces New Patent Application for Rhinochill Technology Paves the Way for New Possibilities

BrainCool AB (publ) Receives Patent Approval for "Shivering" in the EU for the Product BrainCool System

Braincool AB (Publ) Announces International Clinical Study with Rhinochill®System of Patients with Sudden Cardiac Arrest Obtain Ethical Approval

First quarter 2023 earnings released

BrainCool AB (publ) to Report Q3, 2023 Results on Nov 30, 2023

BraincCool Launches New Commercialization Strategy for Its Breakthrough Product Cooral ®System Aiming for Reimbursement in the U.S

Is BrainCool (NGM:BRAIN) In A Good Position To Invest In Growth?

BrainCool AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

Third quarter 2022 earnings released: kr0.17 loss per share (vs kr0.12 loss in 3Q 2021)

Here's Why BrainCool (NGM:BRAIN) Can Afford Some Debt

No independent directors

BrainCool AB (publ) to Report Q3, 2022 Results on Nov 30, 2022

BrainCool AB (publ) Announces FDA approval of Cooral

Second quarter 2022 earnings released: kr0.18 loss per share (vs kr0.13 loss in 2Q 2021)

We Think BrainCool (NGM:BRAIN) Has A Fair Chunk Of Debt

First quarter 2022 earnings released: kr0.14 loss per share (vs kr0.12 loss in 1Q 2021)

BrainCool AB (publ) to Report Q1, 2022 Results on May 31, 2022

No independent directors

CEO & Director recently bought kr73k worth of stock

CEO & Director recently bought kr195k worth of stock

CEO & Director recently bought kr195k worth of stock

CEO & Director recently bought kr195k worth of stock

Is BrainCool (NGM:BRAIN) A Risky Investment?

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 2Q 2020)

CEO & Director recently bought kr238k worth of stock

BrainCool AB (publ), Annual General Meeting, Apr 15, 2021

Full year 2020 earnings released: kr0.68 loss per share (vs kr1.43 loss in FY 2019)

BrainCool AB (publ) Receives FDA "Breakthrough Device" Designation for Cooral® System for Prevention of Oral Mucositis

New 90-day high: kr9.17

How Much Did BrainCool's(NGM:BRAIN) Shareholders Earn From Share Price Movements Over The Last Five Years?

Third quarter 2020 earnings released: kr0.12 loss per share

New 90-day low: kr7.00

Braincool AB Announces Statistically Significant Late-Breaking Clinical Data At SMO Virtual Congress 2020

New 90-day high - kr11.24

BrainCool AB (publ) to Report Q2, 2020 Results on Aug 28, 2020

New 90-day high - kr7.15

CEO

테뉴어

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령